AZD-5363 is primarily used in research and clinical settings as a potent and selective inhibitor of the AKT (protein kinase B) pathway. It plays a significant role in studying cancer biology, as the AKT pathway is often dysregulated in various cancers. By inhibiting AKT, this compound helps researchers understand tumor growth, survival, and resistance to therapies. It is also being explored in clinical trials as a potential therapeutic agent for cancers such as breast, prostate, and ovarian cancer, particularly in cases where PI3K/AKT/mTOR signaling is hyperactive. Additionally, AZD-5363 is utilized to investigate its effects in combination with other treatments, such as chemotherapy or targeted therapies, to enhance anti-cancer efficacy. Its application extends to studying metabolic disorders and other diseases linked to AKT signaling.